$19.0701
+0.07
(+0.37%)▲
Insights on Neogenomics, Inc.
Revenue is up for the last 3 quarters, 137.22M → 151.95M (in $), with an average increase of 5.0% per quarter
Netprofit is up for the last 3 quarters, -30.79M → -18.51M (in $), with an average increase of 29.0% per quarter
In the last 3 years, Iqvia Holdings Inc. has given 5.6% return, outperforming this stock by 66.0%
1.52%
Downside
Day's Volatility :3.25%
Upside
1.75%
54.38%
Downside
52 Weeks Volatility :57.64%
Upside
7.16%
Period | Neogenomics, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 33.9% | -1.3% | 0.0% |
6 Months | 14.53% | 1.2% | 0.0% |
1 Year | 61.02% | -5.7% | -6.5% |
3 Years | -60.42% | 17.1% | -6.5% |
Market Capitalization | 2.4B |
Book Value | $7.45 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -0.77 |
PEG Ratio | 3.02 |
Wall Street Target Price | 21.0 |
Profit Margin | -16.76% |
Operating Margin TTM | -14.52% |
Return On Assets TTM | -4.02% |
Return On Equity TTM | -9.83% |
Revenue TTM | 574.8M |
Revenue Per Share TTM | 4.59 |
Quarterly Revenue Growth YOY | 18.0% |
Gross Profit TTM | 187.9M |
EBITDA | -38.1M |
Diluted Eps TTM | -0.77 |
Quarterly Earnings Growth YOY | 1.31 |
EPS Estimate Current Year | -0.18 |
EPS Estimate Next Year | -0.08 |
EPS Estimate Current Quarter | -0.08 |
EPS Estimate Next Quarter | -0.05 |
What analysts predicted
Upside of 10.12%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 258.6M | ↑ 5.95% |
Net Income | -846.0K | ↓ 85.22% |
Net Profit Margin | -0.33% | ↑ 2.01% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 276.7M | ↑ 7.01% |
Net Income | 2.6M | ↓ 412.06% |
Net Profit Margin | 0.95% | ↑ 1.28% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 408.8M | ↑ 47.73% |
Net Income | 8.0M | ↑ 203.26% |
Net Profit Margin | 1.96% | ↑ 1.01% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 444.4M | ↑ 8.71% |
Net Income | 4.2M | ↓ 47.89% |
Net Profit Margin | 0.94% | ↓ 1.02% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 484.3M | ↑ 8.97% |
Net Income | -8.3M | ↓ 300.07% |
Net Profit Margin | -1.72% | ↓ 2.66% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 509.7M | ↑ 5.24% |
Net Income | -144.3M | ↑ 1628.17% |
Net Profit Margin | -28.3% | ↓ 26.58% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 125.1M | ↑ 6.74% |
Net Income | -35.3M | ↓ 28.55% |
Net Profit Margin | -28.23% | ↑ 13.94% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 128.8M | ↑ 2.97% |
Net Income | -36.9M | ↑ 4.39% |
Net Profit Margin | -28.62% | ↓ 0.39% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 138.7M | ↑ 7.71% |
Net Income | -22.7M | ↓ 38.44% |
Net Profit Margin | -16.36% | ↑ 12.26% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 137.2M | ↓ 1.07% |
Net Income | -30.8M | ↑ 35.74% |
Net Profit Margin | -22.44% | ↓ 6.08% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 146.9M | ↑ 7.07% |
Net Income | -24.3M | ↓ 20.99% |
Net Profit Margin | -16.56% | ↑ 5.88% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 152.0M | ↑ 3.43% |
Net Income | -18.5M | ↓ 23.9% |
Net Profit Margin | -12.19% | ↑ 4.37% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 343.3M | ↑ 1.85% |
Total Liabilities | 137.8M | ↓ 8.45% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 505.0M | ↑ 47.09% |
Total Liabilities | 184.6M | ↑ 33.94% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 709.5M | ↑ 40.49% |
Total Liabilities | 202.1M | ↑ 9.5% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 988.3M | ↑ 39.3% |
Total Liabilities | 294.0M | ↑ 45.49% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 1.9B | ↑ 89.19% |
Total Liabilities | 761.5M | ↑ 158.98% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 1.7B | ↓ 6.94% |
Total Liabilities | 742.0M | ↓ 2.56% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.8B | ↓ 2.05% |
Total Liabilities | 748.6M | ↓ 0.79% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.8B | ↓ 2.04% |
Total Liabilities | 742.6M | ↓ 0.8% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.7B | ↓ 0.89% |
Total Liabilities | 742.0M | ↓ 0.08% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.7B | ↓ 1.77% |
Total Liabilities | 734.7M | ↓ 0.98% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.7B | ↓ 0.82% |
Total Liabilities | 738.9M | ↑ 0.57% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.7B | ↓ 1.0% |
Total Liabilities | 730.8M | ↓ 1.1% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 18.0M | ↓ 16.02% |
Investing Cash Flow | -13.7M | ↑ 110.58% |
Financing Cash Flow | -4.1M | ↓ 84.17% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 44.8M | ↑ 148.3% |
Investing Cash Flow | -139.7M | ↑ 920.36% |
Financing Cash Flow | 92.0M | ↓ 2345.64% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 23.4M | ↓ 47.82% |
Investing Cash Flow | -19.6M | ↓ 85.95% |
Financing Cash Flow | 159.5M | ↑ 73.41% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.5M | ↓ 93.75% |
Investing Cash Flow | -159.4M | ↑ 712.23% |
Financing Cash Flow | 235.6M | ↑ 47.74% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -26.7M | ↓ 1930.34% |
Investing Cash Flow | -632.4M | ↑ 296.62% |
Financing Cash Flow | 725.3M | ↑ 207.85% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -66.0M | ↑ 146.95% |
Investing Cash Flow | 517.0K | ↓ 100.08% |
Financing Cash Flow | 11.8M | ↓ 98.37% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -17.0M | ↓ 41.47% |
Investing Cash Flow | -6.3M | ↓ 152.06% |
Financing Cash Flow | 1.0M | ↓ 83.31% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -16.3M | ↓ 4.26% |
Investing Cash Flow | -4.2M | ↓ 33.09% |
Financing Cash Flow | 3.0M | ↑ 192.68% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -3.7M | ↓ 77.35% |
Investing Cash Flow | -1.1M | ↓ 74.68% |
Financing Cash Flow | 1.8M | ↓ 39.1% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -12.7M | ↑ 244.42% |
Investing Cash Flow | 23.7M | ↓ 2333.49% |
Financing Cash Flow | 1.4M | ↓ 23.47% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -1.5M | ↓ 87.8% |
Investing Cash Flow | 14.9M | ↓ 37.04% |
Financing Cash Flow | 64.0K | ↓ 95.36% |
Sell
Neutral
Buy
Neogenomics, Inc. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Neogenomics, Inc. | 29.69% | 14.53% | 61.02% | -60.42% | 20.1% |
![]() Idexx Laboratories, Inc. | 14.08% | 3.72% | 14.28% | 5.57% | 145.22% |
![]() Agilent Technologies Inc. | 19.77% | 8.82% | -15.66% | 11.85% | 76.64% |
![]() Thermo Fisher Scientific, Inc. | 9.03% | -4.33% | -10.96% | 4.53% | 103.42% |
![]() Danaher Corp. | 14.3% | -4.14% | -16.6% | -0.42% | 110.24% |
![]() Iqvia Holdings Inc. | 9.33% | 6.32% | 2.35% | 27.14% | 76.13% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Neogenomics, Inc. | NA | NA | 3.02 | -0.18 | -0.1 | -0.04 | 0.0 | 7.45 |
![]() Idexx Laboratories, Inc. | 48.79 | 48.79 | 7.21 | 9.84 | 0.93 | 0.24 | 0.01 | 15.62 |
![]() Agilent Technologies Inc. | 33.15 | 33.15 | 2.36 | 5.41 | 0.22 | 0.08 | 0.01 | 20.01 |
![]() Thermo Fisher Scientific, Inc. | 32.16 | 32.16 | 4.28 | 21.56 | 0.13 | 0.05 | 0.0 | 117.32 |
![]() Danaher Corp. | 27.92 | 27.92 | 3.24 | 7.55 | 0.12 | 0.05 | 0.0 | 70.93 |
![]() Iqvia Holdings Inc. | 35.36 | 35.36 | 1.48 | 10.19 | 0.2 | 0.05 | 0.0 | 31.81 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Neogenomics, Inc. | Buy | $2.4B | 20.1% | NA | -16.76% |
![]() Idexx Laboratories, Inc. | Buy | $39.7B | 145.22% | 48.79 | 22.93% |
![]() Agilent Technologies Inc. | Buy | $37.0B | 76.64% | 33.15 | 18.15% |
![]() Thermo Fisher Scientific, Inc. | Buy | $189.6B | 103.42% | 32.16 | 13.68% |
![]() Danaher Corp. | Buy | $163.6B | 110.24% | 27.92 | 20.01% |
![]() Iqvia Holdings Inc. | Buy | $38.5B | 76.13% | 35.36 | 7.51% |
BlackRock Inc
Vanguard Group Inc
Brown Advisory Holdings Inc
HHG PLC
T. Rowe Price Investment Management,Inc.
State Street Corporation
Neogenomics, Inc.’s price-to-earnings ratio stands at None
Read Moreneogenomics laboratories is a leading cancer diagnostic reference laboratory that has provided high-quality cancer testing and partnership programs to pathologists and oncologists for over 10 years. we work every day to achieve our common purpose of saving lives by improving patient care through communication, accuracy, reliability, and efficiency. our areas of expertise include cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor fish testing with the largest menu of technical-only services available; 10-color flow cytometry; ihc supported by an extensive antibody library; and over 100 molecular oncology tests comprising the most comprehensive combination of multiparameter profiles and targeted biomarker tests in the industry. our technical-only testing programs feature on-demand or live training and are available to pathologists who wish to sign out fish, flow cytometry, and/or ihc. neogenomics’ extremely fast test development cycle means we are hig
Organization | Neogenomics, Inc. |
Employees | 2100 |
CEO | Mr. George A. Cardoza |
Industry | Health Services |